Background
==========

Dyschromatosis symmetrica hereditaria (DSH, MIM \#127400), also called symmetric dyschromatosis of the extremities, is characterized by hyperpigmented and hypopigmented macules on the face and dorsal aspects of the extremities. The skin lesions usually appear from infancy or early childhood, commonly stop spreading before adolescence and last for life \[[@B1]\]. Generally showing an autosomal dominant pattern of inheritance with high penetrance, DSH has been reported in various parts of the world, but predominantly in Japan and China \[[@B2],[@B3]\]. RNA-specific adenosine deaminase 1 (ADAR1) gene, located on chromosome 1q21.3, was identified to be responsible for DSH \[[@B2]\].

*ADAR1*, also called *DSRAD* (double-stranded RNA-specific adenosine deaminase), spans 30 kb and contains 15 exons \[[@B4]\]. It encodes RNA-specific adenosine deaminase 1 composed of 1226 amino acid residues, with a calculated molecular mass of 139 kDa. Mammalian *ADAR1* shows ubiquitous expression and is supposed to be one of the housekeeping genes. The enzyme catalyses the deamination of adenosine (A) to isosine (I) in double-stranded RNA substrates, which results in the creation of alternative splicing sites or alternations of codon and thus lead to functional changes in proteins \[[@B4]\].

In this study, we investigated seven families with DSH in Chinese Han population and found five novel and two recurrent mutations. We applied *in vivo* mRNA assays and *in vitro* expression assays to investigate the effects of these novel mutations and discussed their potential pathogenic mechanisms.

Methods
=======

Sample collection and ethics statement
--------------------------------------

Seven unrelated multi-generation DSH families exhibited an autosomal dominant inherence patterns (Figure [1](#F1){ref-type="fig"}). All affected individuals had typical macules on the dorsal aspects of the hands and feet. These lesions, with irregular shapes and sizes, appeared from early childhood, generally ranging from 3 to 10 years (Figure [2](#F2){ref-type="fig"}A, [2](#F2){ref-type="fig"}B). The skin lesions became more pronounced after sun exposure. No patient had extracutaneous symptoms. In family 3, the affected individuals had hypopigmented and hyperpigmented macules around ankle and in family 4 and 5, small freckle-like pigmented macules disturbed on the faces of affected individuals. DSH was diagnosed by experienced dermatologists based on the typical manifestations. The study was approved by the Research Ethics Committee of China Medical University and all the participants gave written informed consent.

![**Family Pedigrees in this study.** Seven multi-generation families with DSH illustrated autosomal dominant inherence pattern with 29 affected individuals. **(A-G)** Pedigrees of the studied DSH family 1-7. Affected family members are presented by black symbols. The probands are arrowed.](1471-2350-15-69-1){#F1}

![**Typical skin lesions and mutations of the*ADAR1*gene. (A, B)** A mixture of hyperpigmented and hypopigmented macules distributed on the dorsal aspects of hands and feet of the proband of family 4 (III1); **(C-G, I-J)** Direct DNA sequencing showing the five novel mutations in the family 1--5 **(C-G)** and the two recurrent mutations in family 6 and 7 **(I, J)**, respectively; **(H)** ClustaIW multiple alignment of various species around residue 1001 of human ADAR1.](1471-2350-15-69-2){#F2}

Extraction of genomic DNA and PCR
---------------------------------

Genomic DNA samples were extracted from peripheral blood using the Universal Genomic DNA Extraction Kit (TaKaRa, Dalian, China). The primers that flanked all 15 coding exons and intron-exon boundaries of the *ADAR1* were designed (Table [1](#T1){ref-type="table"}). Using Taq DNA polymerase, all fragments were amplified as follows: 1 min at 94°C, 30 cycles (30 sec at 94°C, 30 sec at 58°C, 1 min at 72°C) and 5 min at 72°C. After the amplification, the products were purified on agarose gels and subjected to sequencing.

###### 

**Primers and conditions used in PCR for*ADAR1*gene**

  **Exon**   **Primers (5′ → 3′)**                 **Product size (bp)**   **Annealing temperature (°C)**
  ---------- ------------------------------------- ----------------------- --------------------------------
  1          Forward: ACTTCCAGTGCGGAGTAGCGGAG      221                     66
             Reverse: CAAGACGCACACGCTACGCACTGC                              
  2          Forward: TCAAGGGCTGTTCCACAGGCAGC      1754                    61
             Reverse: TCAGCCAAGACTGCGTCAGGAGC                               
  3-4        Forward: GGCAGAAGGAGTGACCTAGACTC      907                     66
             Reverse: GGTCAATCTGCCATCCCTGAGGAGG                             
  5-6        Forward: AGAGGCTAGGTCAGGCTCCTCAGTC    674                     66
             Reverse: TAAGAGGCCGTGGAGACAGGGCT                               
  7-8        Forward: CATATGTTTGCAAGACTGGCC        835                     63
             Reverse: TGCATGGACTCCAGGGGAGGATGAG                             
  9          Forward: CTGAGGCTGTTTCTGCCTTGAAGC     253                     63
             Reverse: GGGAACTGGAGCTCTCCACAG                                 
  10         Forward: GCCCTCAGCAGAAATGAAGGAGACCC   456                     65
             Reverse: CTCAAACCCACAGTGGAGTGTGGC                              
  11         Forward: CTGCTGTCCACCTCCAGTCTCCCAT    385                     66
             Reverse: CAGCACCTCTGTGCCCAGTGAC                                
  12         Forward: GTGGTTTGGTCCATTGGCGCCTGTG    300                     66
             Reverse: GCATGCAGTTTGGGATCTGGGCAC                              
  13-14      Forward: CTGGTAGCCCCAGTCAGAAGGTGCT    864                     66
             Reverse: GATGCACCCTTGCAAGTCAGGGCAG                             
  15         Forward: ACGGTGTCTCCACTGTGAGCTCCT     372                     63
             Reverse: GCTACGACCTACCTCTCTCACACCC                             

RNA splicing analysis
---------------------

Fresh peripheral blood samples were collected from the affected individual and 3 healthy controls. Total RNA was extracted using the TRIzol reagent according to the manufacturer's protocols. After quantification, 1 μg of RNA sample was reversely transcribed into cDNA using an AMV reverse transcriptase kit from TaKaRa Company according to the manufacturer's instructions. To analyze the expression of the mutant *ADAR1* allele, RT-PCR was performed with primers E2F/E3R (Table [2](#T2){ref-type="table"}) \[[@B5]\]. The cDNA fragments were then subcloned into pMD 18-T vector and subjected with sequencing. Moreover, RT-PCR was carried out with primer pairs E1F/E3R and E1F/E4R to determine whether there was exon skipping in affected individual.

###### 

Primer sequences used in RT-PCR and real-time quantitative RT-PCR

  ------------------ -------------------------------------------
  RT-PCR             E1F: 5′-GAGGAAACGAAAGCGAAATTGAACCGGA-3′
                     E2F: 5′- AACTCCACATCTGCCTTGGAAGATCCTC -3′
                     E3R: 5′-CTCTCGGCCATTGATGACAACCTGGAAT-3′
                     E4R: 5′-TGTGCATACACTCAAGCAGTGTGGTGAC-3′
  Real-time RT-PCR   E9-10 F: 5′-GGCTTCATCAGGTTTCTCTAC-3′
                     E10-11R: 5′-CACGGAGCAGTGCTGATATAC-3′
                     GAPDH-F: 5′-CATCTTCCAGGAGCGAGATC-3′
                     GAPDH-R: 5′-GCAAATGAGCCCCAGCCTTC-3′
  ------------------ -------------------------------------------

Real-time quantitative RT-PCR
-----------------------------

To quantify the relative mRNA expression of *ADAR1* in affected individual, real-time quantitative RT-PCR was carried out using primer pairs E9-10 F/E10-11R (Table [2](#T2){ref-type="table"}). The amplicon of *ADAR1* was 140 bp in length, normalized by a 120-bp *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*) fragment. Reactions were performed with SYBR Green PCR Master Mix (TaKaRa) \[[@B5]\]. Three replicates of each reaction were carried out and the 2^-ΔΔCT^ method was used to calculate relative changes in *ADAR1* expression. Melting curve analysis confirmed that only the expected product was amplified \[[@B5]\].

*In vitro* expression assay
---------------------------

The wild-type coding sequence of *ADAR1* was amplified from pCMV6-ADAR1 (Origene) by PCR and subcloned into pFLAG-CMV-2 (Sigma-Aldrich, St. Louis, MO, USA) at its *Not* I restriction site by standard procedure. To generate mutant plasmids, site-directed mutagenesis using PCR-based method was applied. Concisely, primers were designed for mutagenesis and fragments amplified by PCR were subcloned into pFLAG-CMV-2 vector using a standard subcloning protocol, respectively. After confirmed by sequencing, all plasmids were transfected into human embryonic kidney (HEK-293) cells, respectively \[[@B6]\]. The whole cellular lysates were extracted at 48 h post-transfection and immunoblotting was performed as reported previously \[[@B7]\].

Results
=======

Mutation analysis
-----------------

Among 7 Chinese families with DSH, we found 5 novel mutations in *ADAR1* (Table [3](#T3){ref-type="table"}). The spectrum of mutations included one nonsense mutation, two missense mutations, one small insertion and one small deletion, all of which were heterozygous (Figure [2](#F2){ref-type="fig"}C-G). Searching the Human Gene Mutation Database (HGMD) and PubMed, we did not find the reports about these variants. All the mutations segregated affected individuals from 100 normal Chinese subjects, suggesting that neither of them was a polymorphism (For point mutations c.556C \> T, c.3001C \> T and c. 1601G \> A, PCR-RFLP was applied with restriction endonuclease *Bsp*1407I, *Bgl* II and *Sca* I while for small insertion/deletion c.1936_1937insTG and c.1065_1068delGACA, SDS-PAGE was applied after PCR amplification, respectively).

###### 

**Mutations of the*ADAR1*gene identified in this study**

  **Patient**   **Part of lesions**              **Mutation**         **Mutation effect**        
  ------------- -------------------------------- -------------------- --------------------- ---- ------------
  1             Back of hands and feet           c.556C \> T          p.Gln186X             2    Nonsense
  2             Back of hands and feet           c.3001C \> T         p.Arg1001Cys          11   Missense
  3             Back of hands and feet, ankles   c.1936_1937insTG     p.Phe646LeufsX16      5    Frameshift
  4             Back of hands and feet, face     c.1065_1068delGACA   p.Asp357ArgfsX47      2    Frameshift
  5             Back of hands and feet, face     c.1601G \> A         p.Gly471AspfsX30      2    Splicing
  6             Back of hands and feet           c.2744C \> T         p.Ser915Phe           9    Missense
  7             Back of hands and feet           c.3463C \> T         p.Arg1155Trp          15   Missense

In the family 1, the nonsense mutation was detected in exon 2 of *ADAR1* and defined as c.556C \> T (Figure [2](#F2){ref-type="fig"}C). This mutation was suggested leading to a truncated ADAR1 protein lacking 1040 amino acid residues. In the family 2, the missense mutation in exon 11, c.3001C \> T, was identified by sequencing (Figure [2](#F2){ref-type="fig"}D). This mutation replaced arginine residue with cysteine, which was shown as a highly conserved residue within the functional domain of the ADAR1 (Figure [2](#F2){ref-type="fig"}H).Moreover, nucleotides TG were found to insert between c.1936 and c.1937 in the family 3 and this 2-bp small insertion induced a frameshift from codon 646 and expected to produce a premature termination codon (PTC) at codon 661 (Figure [2](#F2){ref-type="fig"}E). In addition, one 4-bp small deletion, c.1065_1068delGACA, was detected in the family 4. This mutation might shift the reading frame and generate a PTC at codon 403 (Figure [2](#F2){ref-type="fig"}F).

Furthermore, direct sequencing of *ADAR1* revealed a missense substitution, c. 1601G \> A, at the end of exon 2 in the family 5 (Figure [2](#F2){ref-type="fig"}G). Since this G nucleotide belongs to the conserved exon-intron junction, we performed splicing predictions with web-based resources. Analysis with SpliceView (<http://zeus2.itb.cnr.it/~webgene/wwwspliceview_ex.html>) and Human Splicing Finder (<http://www.umd.be/HSF/>) indicated that the recognition of such splice donor site was potentially attenuated in the presence of c.1601G \> A, supporting that this mutation might play a role in splicing process.

Moreover, two recurrent mutations, c.2744C \> T and c.3463C \> T, were detected in family 6 and 7, respectively (Figure [2](#F2){ref-type="fig"}I, [2](#F2){ref-type="fig"}J). Both of them were missense mutations, suggesting the replacements of serine 915 by phenylalanine and arginine 1155 by tryptophan, respectively \[[@B8],[@B9]\].

Molecular analysis of expression patterns of the novel mutations
----------------------------------------------------------------

Furthermore, we attempted to determine the exact consequence of the c.1601G \> A mutation in splicing with *in vivo* mRNA assays. RT-PCR analysis revealed differential splicing patterns between affected individual and healthy control. While predicted 780-bp PCR fragments of normal splicing were shown and confirmed by sequencing analysis both in the affected and healthy individual, an additional about 600-bp PCR product was shown in the presence of mutant and subsequently subcloned into pMD18-T (Figure [3](#F3){ref-type="fig"}A, [3](#F3){ref-type="fig"}B). Direct sequencing of TA clones revealed that this mutation caused a splicing error in *ADAR1*. With functional loss of the native intron 2 donor site, this mutation activated the cryptic splicing donor site GT lying upstream of the normal splicing donor site in exon 2 and thus caused a 190-bp deletion in mRNA sequence (Figure [3](#F3){ref-type="fig"}C). Hence, this c.1601G \> A mutation was expected to shift the reading frame from codon 471 with 29 aberrant amino acids and generate premature termination at codon 500. Moreover, no additional band was detected in RT-PCR assays using the primer pairs E1F/E3R and E1F/E4R, excluding the possibility of exon skipping in affected individual due to this mutation (data not shown).

![**Aberrant splicing pattern of*ADAR1*caused by c.1601G \> A mutation. (A)** Locations of primers used in RT-PCR; **(B)** RT-PCR analysis revealed a transcript abnormality in *ADAR1*; **(C)** cDNA sequencing and predicted amino acid sequence of the aberrant (left) and normal (right) transcripts of *ADAR1*; **(D)** The relative quantities of *ADAR1* mRNA level derived from real-time quantitative RT-PCR.](1471-2350-15-69-3){#F3}

Upon the worthwhile observation that the aberrant transcript was present at much reduced level in the affected individual, mRNA quantification was evaluated with real-time quantitative RT-PCR. By validating with the 2^-ΔΔCT^ method, the relative quantities were 0.525, 0.639 and 0.467 (mean ± SD, 0.54 ± 0.09) for individual carrying with c.1601G \> A mutation compared with healthy subject, indicating an approximately 50% reduction of the *ADAR1* mRNA expression in affected individual.

Since fresh blood samples from affected individuals of family 1 to 4 were not available, we continued to investigate the expression patterns of these mutants with *in vitro* expression assays. Briefly, immunoblottings were performed with lysates of HEK-293 cells overexpressing wild-type or mutants of *ADAR1*. Consistent with the predicted results, the truncated ADAR1 proteins were detected as 21 kDa in cells overexpressing c.556C \> T mutation, 75 kDa in cells overexpressing c.1936_1937insTG mutation and 46 kDa in cells overexpressing c.1065_1068delGACA mutation, respectively (Figure [4](#F4){ref-type="fig"}). Moreover, as a missense mutation, c.3001C \> T (p.Arg1001Cys) mutant demonstrated the same molecular weight as the wild-type ADAR1 protein.

![***In vitro*expression assays.** Total cellular lysates of HEK-293 cells transfected with FLAG-tagged wild-type or mutant plasmids were immunoblotted with FLAG antibody. beta-tubulin was used as an internal control.](1471-2350-15-69-4){#F4}

Discussion
==========

A-to-I RNA editing is one of the post-transcriptional modifications widespread in mammals, which modifies adenosine (A) base in pre-mRNA to yield inosine (I) \[[@B10]\]. Since I is recognized as guanosine during translation, A-to-I RNA editing in coding sequences probably leads to amino acid changes which often entails changes in protein function \[[@B10]\]. Moreover, editing A-to-I modification might alter splice patterns as well as RNA structures and stabilities \[[@B1],[@B10],[@B11]\]. A-to-I editing is catalyzed by ADARs in vertebrate and till now, three ADAR family members, ADAR 1--3, have been identified. Among them, *ADAR1* was confirmed to be responsible for DSH in 2003 \[[@B1]\]. To date, the mechanisms by which *ADAR1* mutations cause DSH still remain unclear \[[@B10],[@B11]\].

Human ADAR1 contains, from N- to C-terminals, two adenosine deaminase Z-alpha (Zα) domains, three double-stranded RNA binding motifs (DSRMs) and a tRNA-specific and double-stranded RNA adenosine deaminase (ADEAMc) domain, which encodes by exon 2, 2--7 and 9--15 of *ADAR1*, respectively \[[@B5]\]. Although ADEAMc is the catalyze domain for A-to-I modification, Zα and DSRM domains are also essential for the activity of ADAR1 \[[@B5],[@B11]-[@B14]\].

In this study, we reported five novel mutations and two recurrent mutations. Among them, the nonsense mutation c.556C \> T (p.Gln186X) and small deletion c.1065_1068delGACA (p.Asp357ArgfsX47) are expected to cause ADAR1 truncations lacking the entire three DSRMs and ADEAMc domain while c.1936_1937insTG (p.Phe646LeufsX16), the small insertion identified in our study, supposes to change the reading frame from the second DSRM and induces truncated ADAR1 protein without the last DSRM and ADEAMc domain (Figure [5](#F5){ref-type="fig"}). In addition, Figure [4](#F4){ref-type="fig"} suggested that the mutations c.556C \> T and c.1065_1068delGACA might reduce the expression of mutant proteins and we speculated that the nonsense-mediated mRNA decay (NMD) might be one of the possibilities. For the missense mutations c.3001C \> T (p.Arg1001Cys), c.2744C \> T (p.Ser915Phe) and c.3463C \> T (p.Arg1155Trp), the transitions of nucleotides change codons in the highly conserved region of ADEAMc domain, which possibly alter the activity of ADAR1 directly, or by disturbing the formation of wild-type ADAR1 homodimers \[[@B9]\]. In family 5, the aberrant splicing decreased approximately half *ADAR1* mRNA level, potentially caused by NMD, supporting that haploinsufficiency of *ADAR1* produces DSH \[[@B5],[@B9]\]. In addition, we compared the clinical features with the mutations indentified in all the families but failed to find any clear relationship between phenotypes and genotypes as other groups have reported \[[@B2],[@B13]\].

![**Novel mutations of*ADAR1*identified in this study.** The functional domains (Zα, DSRM, ADEAMc) were indicated in the figure. Zα: Z-DNA binding domains; DSRM: double stranded RNA binding domains; ADEAMc: deaminase domain.](1471-2350-15-69-5){#F5}

Till now, about 145 *ADAR1* mutations have been reported in DSH patients, which consist of 80 missense and nonsense mutations, 11 splicing mutations, 37 small deletions, 14 small insertions, 2 small indels and 1 gross insertion \[[@B15]-[@B29]\]. So far, most known missense mutations (49 in 57, 86%) are located within the ADEAMc domain encompassing amino acids 839--1222 \[[@B3]\]. The missense mutations identified in our study are also located in this domain. These data support that the ADEAMc domain is critical for this enzyme and indicates that this region might be hot spot for mutation within *ADAR1*\[[@B10],[@B16],[@B17]\]. To date, 23 nonsense mutations have been reported in *ADAR1* and they appear to distribute throughout the gene without apparent unifying connection. Till now, 11 splicing mutations have been identified, all of which situate in *ADAR1* introns. Among them, only 4 mutations were further studied with cDNA sequence analysis and detected the aberrant splicing products \[[@B20],[@B21],[@B27]\], in which 3 splicing mutations led to skipping one or more exons near to the mutations \[[@B27]\], and the other one was a in-frame mutation which generated a 4-amino acid deletion in ADAR1 protein \[[@B21]\]. To our knowledge, the c.1601G \> A mutation identified in our study is the first report about the exonic splicing mutation in *ADAR1*.

Although ADAR1 expressed ubiquitously in mammalian tissues and playing various roles such as viral host defense, embryonic development, tumor growth and miRNA processing \[[@B22]-[@B25]\], only a few its target genes including the neurotransmitter receptors in the central nervous system and the hepatitis virus antigen in the liver are identified \[[@B9]\]. Therefore, mutations in the *ADAR1* might associate with neurological dysfunction such as dystonia and mental deterioration \[[@B26]\]. However, like most affected individuals reported previously, patients in our study only show pigmentary abnormality in skin without obvious dysfunction in extracutaneous tissues. Recently, mutations identified in *ADAR1* were reported to be relevant with autoimmune disorder, hair color change and dental abnormality \[[@B15],[@B27]\]. Thus, further investigation on the mechanisms by which ADAR1 regulates its target genes in different tissues will facilitate the understanding of ADAR1 functions.

Driven by different promoter, ADAR1 has been characterized into two isoforms, an interferon-inducible 150 kDa protein (p150) and a constitutively-expressed 110 kDa protein (p110), in mammalian cells \[[@B1],[@B2]\]. The p150 isoform, translated from the methionine initiation codon, is the full length protein mainly distributed in cytosol while the p110 isoform initially translates from the AUG at codon 296 and locates in the nucleus \[[@B28]\]. Till now, including p.Gln186X identified in our study, four mutations of *ADAR1* have been reported at the 5′ side of codon 296 \[[@B2],[@B29]\]. However, the distinct roles of the isoforms are obscure. Recently, Zhang et al. reported that the small deletion p.R91fsX123 could eliminate the expression of the p150 transcript through NMD, while did not significantly alter the expression of p110 in patients of DSH, indicating that p150 isoform of ADAR1 might be the determinant of DSH \[[@B29]\].

Conclusion
==========

In conclusion, we identified five novel and two recurrent mutations of the *ADAR1* gene in seven Chinese families with DSH and investigated potential effects of the novel mutations in this study. Together with previous related studies, these results might give insight into the still unknown mechanisms leading to DSH. Additionally, our results enrich the *ADAR1* mutation database and will contribute further to the understanding of DSH genotype/phenotype correlations as well as to the pathogenesis of this disease.
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